// App-Quantinova.ai

2387 : Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity

Researchers

Presenter

  • Rebecca A. Marsh

Principal Investigators

  • Kyle Hebert

  • Christopher C. Dvorak

  • Victor Aquino

  • K. Scott Scott Baker

  • Deepak Chellapandian

  • Blachy Davila

  • Christine Duncan

  • Michael J. Eckrich

  • George E. Georges

  • Timothy S. Olson

  • Michael A Pulsipher

  • Shalini Shenoy

  • Elizabeth Stenger

  • Mark Vander Lugt

  • Lolie C. Yu

  • Andrew Gennery

  • Mary Eapen

Medical Centers

  • Bone Marrow Transplant and Immune Deficiency, Cincinnati Childrens Hospital Medical Center, Cincinnati,

  • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

  • The Medical College of Wisconsin, Milwaukee, WI

  • Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California, San Francisco, San Francisco, CA

  • UTSouthwestern Medical Center, Dallas, TX

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • John's Hopkins All Children's Heart Inst, Saint Petersburg, FL

  • Children's Natl Medcl Ctr, Washington, DC

  • Dana-Farber Cancer Institute, Boston, MA

  • Pediatric Blood and Marrow Transplantation Program, Texas Transplant Institute at Medical City Dallas, San Antonio, TX

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Department of Pediatrics, Division of Emergency Medicine, Childrens Hospital of Philadelphia, Philadelphia, PA

  • Children's Hosp Los Angeles, Los Angeles, CA

  • Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO

  • Children's Hosp of Pittsburgh of UPMC, Pittsburgh, PA

  • University of Michigan, Ann Arbor, MI

  • Children's Hospital, NewOrleans, LA

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • Department of Emergency Medicine, Medical College of Wisconsin, Milwaukee, WI

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • Hematocrit

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Alemtuzumab

  • fludarabine tablet

  • Melphalan

  • Busulfan

  • Thiotepa

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved